NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a T-cell-driven lymphoproliferative disorder.
• Characterized by constitutional symptoms, lymphadenopathy, and immune dysregulation including hypergammaglobulinemia and autoantibodies.

Purpose of the Study:

• To describe the clinical, histological, and immunological features of AILD.
• To highlight the spectrum of AILD from benign proliferation to malignant transformation.

Main Methods:

• Diagnosis relies on lymph node biopsy revealing specific architectural and cellular changes.
• Analysis of T-cell receptor and immunoglobulin gene rearrangements.

Main Results:

• Histopathology shows effacement of lymph node architecture, absence of germinal centers, and a polymorphous infiltrate.
• All patients exhibit clonal T-cell receptor or immunoglobulin gene rearrangements.
• AILD represents a stage between benign lymphoid proliferation and overt lymphoma.

Conclusions:

• AILD has a poor prognosis, with a high rate of mortality or progression to lymphoma within two years.
• Current treatments are unsatisfactory due to late-stage immunosuppression and infection risk.